Clinical Trial

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

Highest Rated Children’s Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics…

5 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion…

5 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for…

5 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage…

5 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),…

5 months ago

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE)…

5 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined…

5 months ago

Cognition Therapeutics’ Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive…

5 months ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company…

5 months ago

Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call

DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),…

5 months ago